4//SEC Filing
DUERDEN JOHN H 4
Accession 0001140361-13-017693
CIK 0001375247other
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 2:42 PM ET
Size
6.5 KB
Accession
0001140361-13-017693
Insider Transaction Report
Form 4
DUERDEN JOHN H
Director
Transactions
- Disposition to Issuer
Common Stock
2013-04-25$24.00/sh−13,220$317,280→ 2,206 total - Disposition to Issuer
Common Stock
2013-04-25$24.00/sh−2,206$52,944→ 0 total
Footnotes (1)
- [F1]At the effective time of the merger, these shares of restricted stock immediately vested in full and were converted into the right to receive $24.00 per share in cash, without interest (less any applicable withholding tax), under the terms of the Agrement and Plan of Merger, dated as of March 19, 2013, among the issuer, Odysseus Acquisition Corp, Valeant Pharmaceuticals International and Valeant Pharmaceuticals International, Inc., as amended, and the issuer's 2005 Stock Incentive Plan, as amended, and as approved by the issuer's Board of Directors.
Documents
Issuer
Obagi Medical Products, Inc.
CIK 0001375247
Entity typeother
Related Parties
1- filerCIK 0001296981
Filing Metadata
- Form type
- 4
- Filed
- Apr 28, 8:00 PM ET
- Accepted
- Apr 29, 2:42 PM ET
- Size
- 6.5 KB